January 10th, 2019 - Vandamme et al., 2017, Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial, Human Gene Therapy, Volume 28, No. 11.

“The best trade-off one can currently imagine is to engineer rAAV vectors with better transduction efficiency, carrying optimized therapeutic transgenes and with reduced immunogenic profiles (CpG depleted genome, [Faust et al.], inert capsids, contaminant-free batches, minimum amounts of empty capsids, etc.). Such vectors would provide a higher therapeutic index, as they would permit therapeutic efficiency at doses sufficient to bypass pre-existing humoral immunity, but not high enough to trigger deleterious cellular immunity.”
Click here for full article

Leave a Reply